Nova Patents
EP1576179A4

Methods and compositions for inducing apoptosis in cancer cells

Abstract

Anti-DR5 antibody agonists, combined with apoptosis-inducing agents, synergistically induce apoptosis in cancer cells.

Term

Term ended

Projected expiry passed 25 November 2023, 2.8 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

Every citation, both waysCites: the store holds 6 of 7

Citations
DocumentRelationOfficeCategoryCited duringRelevant claims
WO0183560A1CitesWorld Intellectual Property Organization (WIPO)XASearch report61-64
EP1506011A2CitesEuropean Patent Office (EPO)ESearch report61
EP1506285A2CitesEuropean Patent Office (EPO)ESearch report64
WO0183560ACitesWorld Intellectual Property Organization (WIPO)–––
EP1506011ACitesEuropean Patent Office (EPO)–––
EP1506285ACitesEuropean Patent Office (EPO)–––
GRIFFITH T S ET AL: "FUNCTIONAL ANALYSIS OF TRAIL RECEPTORS USING MONOCLONAL ANTIBODIES", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 162, no. 5, 1 March 1999 (1999-03-01), pages 2597 - 2605, XP000918935, ISSN: 0022-1767Non-patent––Search report–
ICHIKAWA KIMIHISA ET AL: "Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 7, no. 8, August 2001 (2001-08-01), pages 954 - 960, XP002381992, ISSN: 1078-8956Non-patent––Search report–
ASHKENAZI A ET AL: "SAFETY AND ANTITUMOR ACTIVITY OF RECOMBINANT SOLUBLE APO2 LIGAND", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 104, no. 2, July 1999 (1999-07-01), pages 155 - 162, XP000973369, ISSN: 0021-9738Non-patent––Search report–
LIU W ET AL: "Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines.", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY JUL 2001, vol. 25, no. 1, July 2001 (2001-07-01), pages 111 - 118, XP008077364, ISSN: 1044-1549Non-patent––Search report–
POULAKI VASSILIKI ET AL: "REGULATION OF APO2L/TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND-INDUCED APOPTOSIS IN THYROID CARCINOMA CELLS", AMERICAN JOURNAL OF PATHOLOGY, PHILADELPHIA, PA, US, vol. 161, no. 2, August 2002 (2002-08-01), pages 643 - 654, XP008074027, ISSN: 0002-9440Non-patent––Search report–
HUISMAN CYNTHIA ET AL: "Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH FEB 2002, vol. 8, no. 2, February 2002 (2002-02-01), pages 596 - 606, XP008077340, ISSN: 1078-0432Non-patent––Search report–
MONGKOLSAPAYA J ET AL: "STRUCTURE OF THE TRAIL-DR5 COMPLEX REVEALS MECHANISMS CONFERRING SPECIFICITY IN APOPTOTIC INITIATION", NATURE STRUCTURAL BIOLOGY, NEW YORK, NY, US, vol. 6, no. 11, 11 November 1999 (1999-11-11), pages 1048 - 1053, XP008011872, ISSN: 1072-8368Non-patent––Search report–
FULDA S ET AL: "Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 8, no. 8, August 2002 (2002-08-01), pages 808 - 815, XP002251127, ISSN: 1078-8956Non-patent––Search report–
MITSIADES C S ET AL: "TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: Therapeutic applications", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 98, no. 3, 1 August 2001 (2001-08-01), pages 795 - 804, XP002336504, ISSN: 0006-4971Non-patent––Search report–
WEBER TOBIAS ET AL: "Vitamin E succinate is a potent novel antineoplastic agent with high selectivity and cooperativity with tumor necrosis factor-related apoptosis-inducing ligand (Apo2 ligand) in vivo.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH MAR 2002, vol. 8, no. 3, March 2002 (2002-03-01), pages 863 - 869, XP008074026, ISSN: 1078-0432Non-patent––Search report–
KIM K ET AL: "Molecular determinants of response to TRAIL in killing of normal and cancer cells.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH FEB 2000, vol. 6, no. 2, February 2000 (2000-02-01), pages 335 - 346, XP001165608, ISSN: 1078-0432Non-patent––Search report–
ASHKENAZI A: "Targeting death and decoy receptors of the tumour-necrosis factor superfamily", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 2, no. 6, June 2002 (2002-06-01), pages 420 - 430, XP002300582, ISSN: 0028-0836Non-patent––Search report–
KREUZ SEBASTIAN ET AL: "NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling", MOLECULAR AND CELLULAR BIOLOGY, vol. 21, no. 12, June 2001 (2001-06-01), pages 3964 - 3973, XP008074029, ISSN: 0270-7306Non-patent––Search report–